ARDANA ANNOUNCES PRELIMINARY RESULTS IN A PHASE II STUDY OF TEVERELIX LA IN BENIGN PROSTATIC HYPERPLASIA

Edinburgh,  UK, 19 December 2006 : Ardana plc (LSE:ARA), today announces preliminary results from a Phase II study of its lead development compound, the GnRH antagonist Teverelix Long Acting (LA) in benign prostatic hyperplasia (BPH).

Edinburgh,  UK, 19 December 2006 : Ardana plc (LSE:ARA), announces today that Invicorp™ its injectable treatment for erectile dysfunction is now available for sale in Denmark.

Edinburgh,  UK, 19 December 2006 : Ardana plc (LSE:ARA), today announces its Interim Results for the six months ended 30 September 2006.

Edinburgh, UK, 16 November 2006:  Ardana plc (LSE:ARA), announces today that it has commenced the marketing in the United Kingdom of Emselex®, a once a day treatment for symptoms of overactive bladder (OAB) in collaboration with Novartis Pharmaceuticals UK Limited (“Novartis”).

Ardana plc (LSE: ARA) has announced that by 11.00 a.m. on 11 October 2006, being the latest time for receipt of application forms and payment in full under the Open Offer announced on 20 September 2006.

Ardana plc (LSE: ARA.L) (“Ardana or the Company”) confirms that all resolutions put to the Extraordinary General Meeting held on 12 October 2006 were duly passed.

Ardana plc ( LSE: ARA.L) confirms that all resolutions put to the Annual General Meeting on 11 October 2006 were duly passed.

Ardana announces today that it is proposing to raise approximately £9.9 million, net of expenses, by the issue of 9,585,380 New Ordinary Shares at a price of 115 pence per New Ordinary Share.

Edinburgh, UK: 11 September 2006:  Ardana plc (LSE:ARA) today announces preliminary results of its testosterone cream in a Phase II study in hypogonadal men.  A preliminary analysis of the data confirms that Ardana’s testosterone cream is effective in restoring testosterone levels to the normal range in hypogonadal men when administered as a single dose of 2.25g or 4.5g on a daily basis.

Edinburgh, UK: 7 September 2006:  Ardana plc (LSE:ARA), the pharmaceutical company focused on improving human reproductive health, today announces preliminary results of a Phase I study of the Gonadotrophin Releasing Hormone (GnRH) Antagonist, Teverelix LA (Long Acting) in healthy female subjects

Edinburgh, UK, 31 August 2006;  Ardana plc (LSE: ARA), today announces that it has been granted a US patent, number 7,098,305, covering the long acting formulation of its GnRH antagonist, Teverelix (Teverelix LA).

Edinburgh, UK, 29 June, 2006;  Ardana plc (LSE: ARA) today announces the appointment of Dr Huw Jones to its Board of Directors.

Edinburgh, UK, 29 June, 2006;  Ardana plc (LSE: ARA) today announces its Preliminary Results for the year ended 31 March 2006 .

Ardana today announces that application has been made to the UK Listing Authority and the London Stock Exchange for a block listing of 2,494,967 ordinary shares of 1 (one) pence each.  The application is in respect of shares to be allotted pursuant to the exercise of options under the Ardana Bioscience Employees’ share option scheme, Ardana Ltd Employees’ share option scheme and certain individual option agreements between Ardana plc and non-executive directors and non-employees.

Ardana today announces positive results of its testosterone cream in a Phase II study in Hypogonadal Men.  This Phase II dose-finding study provided clear evidence of the effectiveness of Ardana’s bi-gel technology for the transdermal delivery of testosterone.

Ardana today announces the appointment of Klaus Falk as VP Sales & Marketing.

Ardana today reports on a pre-Investigational New Drug (IND) meeting with the US Food and Drug Administration (FDA) to discuss the development of its novel cream for testosterone replacement in male hypogonadism.